论文部分内容阅读
[目的]探讨康复新液联合枯草杆菌二联胶囊辅助治疗活动期轻中度溃疡性结肠炎(UC)的疗效及安全性。[方法]选取2012年2月~2015年8月我院消化内科收治的活动期轻、中度UC患者60例,随机分为治疗组和对照组,每组各30例。对照组患者单独使用美沙拉嗪治疗,治疗组患者在对照组基础上加用康复新液保留灌肠联合枯草杆菌二联胶囊口服治疗,疗程均为8周,比较2组患者临床疗效及疗程结束后肠镜复查结果。[结果]治疗组总有效率明显高于对照组(100%vs.83.3%,96.6%vs.76.7%),差异有统计学意义(P<0.05);2组患者均未出现明显严重不良反应。[结论]康复新液联合枯草杆菌二联胶囊辅助治疗活动期轻中度UC的疗效较为显著,值得临床推广应用。
[Objective] To investigate the curative effect and safety of Kangfuxin combined with Bacillus subtilis Erlian capsule in the treatment of mild to moderate ulcerative colitis (UC). [Methods] Sixty patients with active and moderate UC admitted to Department of Gastroenterology from February 2012 to August 2015 in our hospital were randomly divided into treatment group and control group, with 30 cases in each group. The patients in the control group were treated with mesalazine alone. The patients in the treatment group were treated with the combination of Rehabilitation New Liquid retention enema and Bacillus subtilis Erlian capsule orally in the treatment group for 8 weeks. The clinical efficacy and the end of treatment were compared between the two groups Colonoscopy review results. [Results] The total effective rate of the treatment group was significantly higher than that of the control group (100% vs.83.3%, 96.6% vs.76.7%), the difference was statistically significant (P <0.05); no obvious serious adverse reactions . [Conclusion] The curative effect of Kangfuxin Solution combined with Bacillus subtilis Erlian Capsule in the active treatment of mild to moderate UC is more significant and worthy of clinical application.